Opinion|Videos|April 1, 2025
Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
Listen
0:00 / 0:00
Jack R. Andrews, MD; Eugene B. Cone MD; and Edwin Posadas, MD, FACP, discuss how early intervention with individualized treatment approaches based on disease volume, patient characteristics, and biomarkers significantly improves survival outcomes in metastatic hormone-sensitive prostate cancer.
Advertisement
Timecodes
1:35 Individualized Care for PC
9:24 Frailty & Comorbidities in PC
12:27 Molecular Testing in PC
18:10 Sequencing in PC
22:00 Doublets/Triplets in mHSPC
30:00 Subgroups in mHSPC
39:00 ARASENS Subgroup Analysis
43:55 Future of mHSPC Care
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Urology Times
1
Managing BPH Before Prostate Radiotherapy: Options Compared
2
Patient Selection and Partnership in Prostate Radiotherapy Spacing
3
The role of diet and lifestyle in prostate cancer care, with Lorelei A. Mucci, ScD, MPH
4
Alternative BCG strains may help address ongoing supply challenges in NMIBC
5